{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}],"title":"patients with worst AE grade 1"},{"measurements":[{"groupId":"OG000","value":"7"}],"title":"patients with worst AE grade 2"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"patients with worst AE grade 3"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"patients with worst AE grade 4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Patients were evaluated according to Common Terminology Criteria for Adverse Events (CTCEA). An adverse event (AE) is an abnormal clinical finding. Each participant was assessed from start of treatment until 6 months after the last vaccine.","groups":[{"description":"One ARG1-vaccine every third week for 45 weeks.\n\nARG1-18,19,20: 300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide","id":"OG000","title":"ARG1-18,19,20 Peptide Vaccine"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"0 - 75 weeks","title":"Adverse Events Evaluated by CTCAE 4.0","type":"PRIMARY","unitOfMeasure":"Participants"}